European Society
For Medical Oncology

Most patients were on active anticancer treatment during the 28 days before the administration of third dose

Findings from the international metastatic renal cell database consortium

Stimufend is a biosimilar, highly similar to the reference product Neulasta (pegfilgrastim), which was authorised in the EU in 2002

Improvements also observed with respect to key secondary endpoints, with no increase in adverse events

EMA starts safety review of Janus kinase inhibitors used for inflammatory disorders

Additional declines in cancer mortality rates predicted for 2022

The study primary endpoint is event-free survival, and lack of improvement in pathologic complete response may be misleading as to the impact of atezolizumab on long-term efficacy in high-risk triple-negative breast cancer

Findings from the Danish Breast Cancer Group

Final results from the FIGHT-101 study

ESMO announces a new series of resources designed to guide physicians in areas of oncological practice not covered by guidelines, where current evidence is insufficient to evenly inform clinical decision-making

The ESMO Targeted Anticancer Therapies Congress 2022, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.

Open-source approach leveraging ESMO tools can inform sustainable healthcare spending to benefit national populations worldwide

Death rates from ovarian cancer are predicted to fall by 17% in 2022 in the UK and by 7% in EU countries in 2022 compared to 2017

The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.

The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.

Results of the ESMO Women for Oncology monitoring and authorship studies

The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.

Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose 

ESMO President will act as an Advisor

Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on  

ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people

The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research

Who will be the next ESMO Awardees? Submit your nominations before 9 March.

ESMO has announced today that the 2022 ESMO TAT Honorary Award is presented to Lesley K Seymour 

ESMO delivered an official statement at the Special Session of the World Health Assembly to strengthen pandemic prevention, preparedness and response

The ESMO Immuno-Oncology Congress will be an online-only meeting